Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future oncology (London, England)（2023）
摘要
Overall, STRIDE is more effective than sorafenib for people with unresectable HCC. NCT03298451 (HIMALAYA) (ClinicalTrials.gov).
更多查看译文
关键词
clinical trial, durvalumab, hepatocellular carcinoma, immunotherapy, lay summary, liver cancer, plain language summary, Sorafenib, tremelimumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要